Published 3 days ago • loading... • Updated 21 hours ago

Atsena gets Bain's support in $150M Series C to thwart blindness with gene therapy

Summary by Endpoints News

There's still money to be raised by gene therapy startups with good clinical data. On Wednesday, North Carolina biotech Atsena Therapeutics said it had raised a $150 million Series C to try and be the ...

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

5 Articles

All

Left

Center

Right

FinSMEs

Atsena Therapeutics Raises $150M in Series C Financing

Atsena Therapeutics, a Durham, NC-based clinical-stage gene therapy company, raised $150M in Series C funding. The round was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management, and existing investors including Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, and the Manning […] The post Atse…

21 hours ago

Read Full Article

pharmaceutical-technology.com

Atsena closes $150m to progress gene therapy programmes

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ATSN-201.

2 days ago

Read Full Article

Eyewire+

Atsena Therapeutics Secures $150 Million to Advance Investigational Ocular Gene Therapy

Atsena Therapeutics has closed an oversubscribed $150 million Series C financing, which will be used to advance Atsena’s lead gene therapy program, ATSN-201, aimed at treating X-linked retinoschisis (XLRS). Additionally, the funds will support Atsena’s preclinical pipeline of therapies and the further development of its proprietary spreading AAV.SPR capsid technology. “Closing our Series C marks a pivotal moment for Atsena as we advance our tran…

2 days ago

Read Full Article

Inside Precision Medicine

Atsena Therapeutics Secures $150M to Progress Eye Gene Therapies

North Carolina-based Atsena Therapeutics has secured $150 million in Series C funding to progress its two lead eye gene therapy candidates to the clinic. The company has a candidate therapy, ATSN-201, for X-linked retinoschisis (XLRS), a rare X-linked retinal disease that usually begins in childhood and later leads to blindness, that is currently in a Phase I/II trial. The company also has a candidate therapy, ATSN-101, for another rare inherite…

3 days ago

Read Full Article